Daru-Rito Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in Description.
Use in patients with severe (Child-Pugh Class C) hepatic impairment.
Concomitant treatment with any of the following medicinal products is contraindicated given the expected decrease in plasma concentrations of darunavir and ritonavir and the potential for loss of therapeutic effect (see Precautions and Interactions).
Applicable to darunavir boosted with ritonavir: The combination product lopinavir/ritonavir (see Interactions).
The strong CYP3A inducers rifampicin and herbal preparations containing St John's wort (Hypericum perforatum). Co-administration is expected to reduce plasma concentrations of darunavir and ritonavir which could lead to loss of therapeutic effect and possible development of resistance (see Precautions and Interactions).
Darunavir boosted with ritonavir inhibits the elimination of active substances that are highly dependent on CYP3A for clearance, which results in increased exposure to the co-administered medicinal product. Therefore, concomitant treatment with such medicinal products for which elevated plasma concentrations are associated with serious and/or life-threatening events is contraindicated (applies to Darunavir boosted with ritonavir). These active substances include e.g.: alfuzosin (alpha 1-adrenoreceptor antagonist); amiodarone, bepridil, dronedarone, quinidine, ranolazine, systemic lidocaine (antiarrhythmics/antianginals); astemizole, terfenadine (antihistamines); colchicine when used in patients with renal and/or hepatic impairment (antigout) (see Interactions); ergot derivatives (e.g. dihydroergotamine, ergometrine, ergotamine, methylergonovine); cisapride (gastrointestinal motility agents); pimozide, quetiapine, sertindole (antipsychotics/neuroleptics) (see Interactions); triazolam, midazolam administered orally (sedatives/hypnotics) (for caution on parenterally administered midazolam, see Interactions); sildenafil-when used for the treatment of pulmonary arterial hypertension, avanafil (PDE-5 inhibitors); simvastatin and lovastatin (HMG-CoA reductase inhibitors) (see Interactions); ticagrelor (antiplatelets) (see Interactions).